Greenwich LifeSciences, Inc.
Business
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on advancing GLSI-100 (GP2 peptide plus GM‑CSF) through its Phase III Flamingo-01 trial to prevent breast cancer recurrences. Its main product candidate is GP2, a HER2/neu transmembrane peptide administered with the immunoadjuvant GM‑CSF as an intradermal vaccine, together with clinical development and regulatory activities. Key business activities include clinical trial execution, regulatory filings, intellectual property licensing with the Henry M. Jackson Foundation, and outsourced manufacturing. The company conducts trials and seeks regulatory approval in the U.S. and Europe with plans for global site expansion and potential commercialization via partners or contract sales/distributors.
Summary from filing dated 2025-04-15
Financials
Consolidated Statement of Income
| Concept | Trend | Dec 31, 2025 2025-12-31 | Dec 31, 2024 2024-12-31 |
|---|---|---|---|
| Revenue | — | — | |
| Operating expenses | — | — | |
| Research and Development Expense | 17 | 15 | |
| Selling, General and Administrative Expense | 2 | 2 | |
| Total operating expenses | 19 | 18 | |
| Loss from operations | −19 | −18 | |
| Interest and Dividend Income (Non-Bank) | 89,700 | 223,008 | |
| Net loss | −19 | −17 | |
| Per share information: | — | — | |
| Earnings Per Share (Basic) | −1.43 | −1.34 | |
| Earnings Per Share (Diluted) | −1.43 | −1.34 | |
| Weighted Average Shares Outstanding | 14 | 13 | |
| Weighted Average Shares Outstanding, Diluted | 14 | 13 |
Consolidated Balance Sheet
| Concept | Trend | Dec 31, 2025 2025-12-31 | Dec 31, 2024 2024-12-31 |
|---|---|---|---|
| Assets | — | — | |
| Current assets | — | — | |
| Cash and Cash Equivalents | 6 | 4 | |
| Total current assets | 6 | 4 | |
| Intangible Assets | — | 1,779 | |
| Total assets | 6 | 4 | |
| Liabilities and stockholders’ equity | — | — | |
| Current liabilities | — | — | |
| Accounts Payable | 5 | 3 | |
| Retirement Related Liabilities, Current | 673,819 | 306,281 | |
| Accrued Compensation and Benefits | 276,496 | 75,916 | |
| Total current liabilities | 6 | 3 | |
| Total liabilities | 6 | 3 | |
| Stockholders’ equity | — | — | |
| Total Stockholders' Equity | 14,299 | 13,153 | |
| Additional Paid-In Capital | 87 | 69 | |
| Retained Earnings | −87 | −68 | |
| Total stockholders’ equity | 353,217 | 908,626 | |
| Total liabilities and stockholders’ equity | 6 | 4 |
Consolidated Statement of Cash Flows
| Concept | Trend | Dec 31, 2025 2025-12-31 | Dec 31, 2024 2024-12-31 |
|---|---|---|---|
| Operating activities: | — | — | |
| Net Income | −19 | −17 | |
| Adjustments required to reconcile net loss to net cash used in operating activities: | — | — | |
| Goodwill Impairment | 1,779 | 3,612 | |
| Stock-based compensation | 7 | 7 | |
| Accounts payable | 2 | 3 | |
| Deferred compensation | 367,538 | 306,281 | |
| Change in Accrued Liabilities | 200,580 | 37,827 | |
| Net cash used in operating activities | −10 | −7 | |
| Sale of common stock via ATM program, net of costs | 12 | 2 | |
| Net proceeds from exercise of remaining underwriter warrants | 145,000 | — | |
| Sale of common stock via Private Placement, net of costs | — | 2 | |
| Net cash provided by financing activities | 12 | 4 | |
| Net increase (decrease) in cash | 2 | −3 | |
| Cash, end of period | — | — | |
| Cash, end of period | — | — |